Medication classes
IL-12/23 inhibitor articles covering treatments such as ustekinumab, including safety, effectiveness, approvals, and access. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
Page 1 of 3 · 98 articles
These development programs could expand treatment choices for Crohn’s disease and may eventually address fibrosis and refractory disease—two major unmet needs. Progress in trials could change management options in coming...
Comparative real-world data may help patients and clinicians weigh expected benefits and risks of risankizumab versus ustekinumab in Crohn’s disease, including effects on steroid-free remission and fistula healing.
Researchers are testing whether targeting fungi with fluconazole can boost how well IL-23 biologics work for Crohn’s disease — if positive, this could point to a new adjunctive strategy to improve responses to biologic...
This real-world multicentre study evaluates risankizumab effectiveness and short-term persistence in adults with Crohn's disease, including those previously treated with ustekinumab — information that can help patients...
This Taiwanese multicenter real-world study reports high 52-week clinical response and remission rates, sustained one-year drug persistence, and meaningful fistula healing with ustekinumab in patients with Crohn’s...
An FDA approval of an autoinjector for ustekinumab may make self‑injection easier and more convenient for people with Crohn’s disease or ulcerative colitis who use this biologic. Changes in delivery format can also...
Patients with UC who fail both anti-TNF and JAK inhibitor therapies have limited options. This report suggests tacrolimus can be used as a short-term bridge or in combination to reach another maintenance drug, with many...
People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.
Many people on ustekinumab who lose response wonder whether increasing dosing frequency helps. This prospective study suggests that empiric intensification to every 4 or 6 weeks raised drug levels and was linked with...
Extraintestinal symptoms such as fatigue and joint pain significantly affect quality of life in Crohn's disease. This review suggests ustekinumab may help reduce fatigue and arthritis/arthralgia more than TNF antagonists...
Ustekinumab is already approved for moderate-to-severe Crohn's disease; this real-world study reports encouraging longer-term clinical, biological, and endoscopic outcomes up to 96 weeks and suggests good treatment...
Children with IBD often wait years for medicines to be approved after adult approvals; this review shows many ongoing paediatric trials for biologics and small molecules that could improve treatment options.
Ustekinumab treats Crohn’s disease and ulcerative colitis; a biosimilar that shows similar pharmacokinetics and safety could expand treatment options and affect availability and cost.
Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...
This study addresses whether being on biologic or small‑molecule IBD drugs before colorectal surgery affects short‑term postoperative complications — a practical concern for patients and clinicians planning surgery.
Patients and clinicians are interested in whether combining two targeted biologic therapies can induce stronger endoscopic healing for people with difficult-to-treat Crohn's disease, and whether benefit can be maintained...
The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...
This case suggests ustekinumab — a commonly used biologic for Crohn’s disease — might rarely be associated with kidney injury (FSGS). Patients and clinicians should be aware of new or worsening edema, proteinuria, or...
Long-term extension trials help show whether a drug’s benefits and safety persist over time. For people with Crohn’s disease, this study focuses on maintaining endoscopic improvement and clinical remission with...
This pooled analysis focuses on children with IBD and reports that ustekinumab was associated with substantial clinical and steroid-free remission rates and a low incidence of serious adverse events—information that may...
The study suggests blood metabolite patterns differ by biologic therapy and identifies candidate biomarkers that might help develop less-invasive monitoring tools for inflammation and treatment effects in Crohn’s...
For people with ulcerative colitis who have already tried and failed one or more advanced therapies, this study suggests upadacitinib may lead to higher rates of steroid-free clinical remission and endoscopic healing...
Measuring mucosal healing across the whole gut with stool markers, ultrasound, and capsule endoscopy may give a clearer picture of whether biologic treatment is working and help guide decisions about continuing or...
This study analyzes thousands of adverse event reports for ustekinumab in Crohn’s disease and highlights infections plus possible cardiovascular and neuropsychiatric signals that clinicians and patients may want to...
People with Crohn’s disease on ustekinumab may be more likely to need intensified dosing if they previously tried biologics or immunomodulators or have had disease longer; this could affect monitoring and planning. For...
People with moderate-to-severe Crohn's disease or ulcerative colitis and their clinicians may want to know how long patients stay on guselkumab in real-world care, since persistence reflects tolerability, benefit, and...
Real‑world studies of ustekinumab help patients and clinicians understand how the drug performs outside clinical trials, including effectiveness for steroid‑free remission and use across different UK care settings.
This registered Phase 2/3 program is evaluating guselkumab (an IL‑23 inhibitor) for moderate–severe Crohn's disease and could expand treatment options if trials show benefit and safety. The studies include clinical and...
This study provides real-world data on how well ustekinumab is kept on treatment and its safety in an Arab IBD population—information that can help patients and clinicians understand longer-term use outside clinical...
Adding partial enteral nutrition to ustekinumab was associated with better clinical, endoscopic, radiologic, and nutritional outcomes at 52 weeks in this multicentre real-world cohort of Crohn’s disease patients. This...
This study suggests that people with PSC-IBD may respond differently to some biologic treatments: infliximab and vedolizumab had similar early effectiveness versus IBD alone, but ustekinumab showed a lower early response...
Market shifts — including more biosimilars, expanding biologic and small-molecule options, and wider online pharmacy access — can affect how quickly and affordably new Crohn’s treatments reach patients. Patients on...
A large network meta-analysis found adalimumab reduces risk of clinical relapse in Crohn’s disease and upadacitinib reduces loss of clinical response; these findings summarize comparative maintenance therapy evidence...
An updated FDA drug label affects how ustekinumab is prescribed and monitored. It confirms Crohn’s disease and ulcerative colitis as approved uses and highlights safety concerns (infections, TB screening, malignancy)...
The trial tests ustekinumab dosing, safety, and pharmacokinetics specifically in children with moderate–severe Crohn’s — information that can affect pediatric treatment options and dosing guidance once results are...
Vulvar Crohn’s is a rare, often treatment-refractory manifestation. Reports that ustekinumab and risankizumab helped patients may expand options for people with cutaneous Crohn’s disease, especially after anti–TNF...
A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...
This review addresses cancer risk tied to IBD treatments, a common and important concern for people on long-term immunosuppression or advanced therapies.
Patients, families, and clinicians can use registry-based predictors to better understand which children with Crohn’s disease may be at higher risk of slower or absent remission, which could inform monitoring and...
The report suggests tofacitinib (a JAK inhibitor), alone or combined with ustekinumab, could be an effective option for some infants with treatment-refractory IOIBD — a population with few evidence-based alternatives. If...
Perianal fistulizing Crohn's disease is difficult to treat and many patients have failed anti-TNF therapy. Evidence that ustekinumab achieves high clinical fistula response and remission rates in a real-world multicenter...
Perianal fistulas are a serious complication of Crohn’s disease with limited high-quality trial evidence. This randomized trial suggests ustekinumab may increase the chance of combined clinical and MRI remission at 12...
This label update affects people with Crohn’s disease or ulcerative colitis because it spells out approved uses, age ranges, and the official dosing schedules and safety warnings for ustekinumab (STELARA). Changes in the...
For people with moderate–severe Crohn’s disease who failed anti‑TNF drugs, this trial suggests risankizumab may achieve higher corticosteroid‑free clinical and endoscopic remission than ustekinumab, which could mean...
This review pools available pediatric data showing ustekinumab can induce and maintain remission after anti‑TNF failure, offering a treatment option for children with refractory IBD. Results are most robust for Crohn’s...
People with Crohn's disease and their clinicians often ask how different treatments affect cancer risk. This large nationwide study provides real-world estimates of absolute excess cancer cases by treatment group, which...
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
An FDA label update for PYZCHIVA adds/clarifies that this ustekinumab product is indicated for Crohn's disease and ulcerative colitis and reiterates safety monitoring steps (for infections and TB) that matter to people...
